Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2018 Filed Sep 19, 2018 21:43 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 279,851 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-013571 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,850 Underlying: Common Stock · 279,851 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| September 18, 2018 Filed Sep 19, 2018 21:43 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
SaleCommon Stock | 279,851 | $70.08 | $19,611,818.15 |
DisclosureSEC source: 0001225208-18-013571 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.0000 to $70.4200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 18, 2018 Filed Sep 19, 2018 21:43 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 279,851 | $36.56 | $10,231,352.56 |
DisclosureSEC source: 0001225208-18-013571 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,801.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:49 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-013520 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:49 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 7,360 | $70.18 | $516,510.82 |
DisclosureSEC source: 0001225208-18-013520 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 55,405.9747 F3 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.7300 to $70.4400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F5 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:49 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 100,000 | $70.18 | $7,017,780.00 |
DisclosureSEC source: 0001225208-18-013520 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.6600 to $70.4200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:49 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionCommon Stock | 100,000 | $36.56 | $3,656,000.00 |
DisclosureSEC source: 0001225208-18-013520 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Exercise / conversionStock Option (right to buy) · Derivative | 19,208 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · derivative · entry 5 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,208 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/7/2011, 5/7/2012 and 5/7/2013. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $37.49 | $0.00 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · derivative · entry 4 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable in equal installments on 2/19/2011, 2/19/2012 and 2/19/2013. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
SaleCommon Stock | 29,208 | $65.20 | $1,904,361.60 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · nonDerivative · entry 3 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,467.08 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Exercise / conversionCommon Stock | 10,000 | $37.49 | $374,900.00 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · nonDerivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,675.08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Exercise / conversionCommon Stock | 19,208 | $33.49 | $643,275.92 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,675.08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2018 Filed Aug 2, 2018 21:07 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
SaleCommon Stock | 5,000 | $65.01 | $325,040.00 |
DisclosureSEC source: 0001225208-18-012200 · doc4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,174.972 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.0065 to $65.015, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:12 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 228,091 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-18-012151 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 228,091 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/7/2011, 5/7/2012 and 5/7/2013. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:12 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
GiftCommon Stock | 18,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-012151 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:12 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
SaleCommon Stock | 228,091 | $65.00 | $14,826,690.51 |
DisclosureSEC source: 0001225208-18-012151 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,697.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.05, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:12 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 228,091 | $33.49 | $7,638,767.59 |
DisclosureSEC source: 0001225208-18-012151 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,788.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 16:06 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 556.0132 | $60.70 | $33,750.00 |
DisclosureSEC source: 0001225208-18-010989 · doc4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,449.4176 Underlying: Common Stock · 556.0132 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 16:06 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 473.6409 | $60.70 | $28,750.00 |
DisclosureSEC source: 0001225208-18-010990 · doc4.xml · derivative · entry 3 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,764.9153 Underlying: Common Stock · 473.6409 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 16:06 UTC |
Noseworthy John HDirector
|
GrantPhantom Stock · Derivative | 473.6409 | $60.70 | $28,750.00 |
DisclosureSEC source: 0001225208-18-010991 · doc4.xml · derivative · entry 2 Noseworthy John H · CIK 0001706596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,924.9153 Underlying: Common Stock · 473.6409 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 16:07 UTC |
THULIN INGE GDirector
|
GrantPhantom Stock · Derivative | 473.6409 | $60.70 | $28,750.00 |
DisclosureSEC source: 0001225208-18-010992 · doc4.xml · derivative · entry 2 THULIN INGE G · CIK 0001263739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,050.5433 Underlying: Common Stock · 473.6409 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 16:07 UTC |
WEEKS WENDELL PDirector
|
GrantPhantom Stock · Derivative | 473.6409 | $60.70 | $28,750.00 |
DisclosureSEC source: 0001225208-18-010993 · doc4.xml · derivative · entry 2 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,424.0253 Underlying: Common Stock · 473.6409 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 16:07 UTC |
Wendell Peter CDirector
|
GrantPhantom Stock · Derivative | 473.6409 | $60.70 | $28,750.00 |
DisclosureSEC source: 0001225208-18-010994 · doc4.xml · derivative · entry 2 WENDELL PETER C · CIK 0001032635 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,454.5463 Underlying: Common Stock · 473.6409 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 14:55 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-010754 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 14:55 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 34,094 | $61.00 | $2,079,785.14 |
DisclosureSEC source: 0001225208-18-010754 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 62,765.9747 F3 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.6100 to $61.3100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F5 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 14:55 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 100,000 | $61.00 | $6,100,160.00 |
DisclosureSEC source: 0001225208-18-010754 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.5900 to $61.3200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 14:55 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionCommon Stock | 100,000 | $36.56 | $3,656,000.00 |
DisclosureSEC source: 0001225208-18-010754 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:25 UTC |
BRUN LESLIE ADirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009918 · doc4.xml · derivative · entry 1 BRUN LESLIE A · CIK 0001217068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,520.1094 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:31 UTC |
Cech Thomas RDirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009919 · doc4.xml · derivative · entry 2 Cech Thomas R · CIK 0001464680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,432.8064 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:31 UTC |
Craig Pamela J.Director
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009920 · doc4.xml · derivative · entry 2 Craig Pamela J. · CIK 0001232910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,857.2724 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:31 UTC |
THULIN INGE GDirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009921 · doc4.xml · derivative · entry 2 THULIN INGE G · CIK 0001263739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,576.9024 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:32 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009922 · doc4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,893.4044 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:32 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009923 · doc4.xml · derivative · entry 3 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,291.2744 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:32 UTC |
Noseworthy John HDirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009924 · doc4.xml · derivative · entry 2 Noseworthy John H · CIK 0001706596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,451.2744 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:33 UTC |
Rothman PaulDirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009925 · doc4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,857.2744 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:33 UTC |
RUSSO PATRICIA FDirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009926 · doc4.xml · derivative · entry 2 RUSSO PATRICIA F · CIK 0001023219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,809.8914 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:33 UTC |
Thompson Craig B.Director
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009927 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,809.8934 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:33 UTC |
WEEKS WENDELL PDirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009928 · doc4.xml · derivative · entry 2 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,950.3844 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:33 UTC |
Wendell Peter CDirector
|
GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009929 · doc4.xml · derivative · entry 2 WENDELL PETER C · CIK 0001032635 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,980.9054 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 15, 2018 Filed May 16, 2018 16:33 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
SaleCommon Stock | 9,972 | $59.66 | $594,963.42 |
DisclosureSEC source: 0001225208-18-009415 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,716.527 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.4500 to $59.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
GrantStock Option (right to buy) · Derivative | 65,872 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008932 · doc4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,872 Underlying: Common Stock · 65,872 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC |
Davis Robert MEVP, Global Svcs & CFO
|
GrantStock Option (right to buy) · Derivative | 139,063 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008933 · doc4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,063 Underlying: Common Stock · 139,063 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
GrantStock Option (right to buy) · Derivative | 73,191 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008934 · doc4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,191 Underlying: Common Stock · 73,191 shares Expires 2028-05-03 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
GrantStock Option (right to buy) · Derivative | 475,743 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008935 · doc4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,743 Underlying: Common Stock · 475,743 shares Expires 2028-05-03 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
GrantStock Option (right to buy) · Derivative | 29,277 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008936 · doc4.xml · derivative · entry 2 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,277 Underlying: Common Stock · 29,277 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
GrantStock Option (right to buy) · Derivative | 62,213 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008937 · doc4.xml · derivative · entry 2 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,213 Underlying: Common Stock · 62,213 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
GrantStock Option (right to buy) · Derivative | 25,617 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008938 · doc4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,617 Underlying: Common Stock · 25,617 shares Expires 2028-05-03 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
GrantRestricted Stock Unit · Derivative | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-008938 · doc4.xml · derivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,636 Underlying: Common Stock · 3,636 shares Expires 2021-05-04 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC |
PERLMUTTER ROGER MExe V-P & Pres, MRL
|
GrantStock Option (right to buy) · Derivative | 146,383 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008939 · doc4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,383 Underlying: Common Stock · 146,383 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:33 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
GrantStock Option (right to buy) · Derivative | 139,063 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008940 · doc4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,063 Underlying: Common Stock · 139,063 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.